121 related articles for article (PubMed ID: 38440724)
21. Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer.
Bhat AA; Goyal A; Thapa R; Almalki WH; Kazmi I; Alzarea SI; Singh M; Rohilla S; Saini TK; Kukreti N; Meenakshi DU; Fuloria NK; Sekar M; Gupta G
Cytokine; 2023 Nov; 171():156376. PubMed ID: 37748333
[TBL] [Abstract][Full Text] [Related]
22. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?
Yiong CS; Lin TP; Lim VY; Toh TB; Yang VS
Biomark Res; 2023 Aug; 11(1):75. PubMed ID: 37612756
[TBL] [Abstract][Full Text] [Related]
24. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
Zang J; Zhang R; Jin D; Xie F; Shahatiaili A; Wu G; Zhang Y; Zhao Z; Du P; Jia S; Chen H; Zhuang G
J Pathol; 2023 Oct; 261(2):198-209. PubMed ID: 37584165
[TBL] [Abstract][Full Text] [Related]
25. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S; Chan SL; Gu S; Bai Y; Ren Z; Lin X; Chen Z; Jia W; Jin Y; Guo Y; Hu X; Meng Z; Liang J; Cheng Y; Xiong J; Ren H; Yang F; Li W; Chen Y; Zeng Y; Sultanbaev A; Pazgan-Simon M; Pisetska M; Melisi D; Ponomarenko D; Osypchuk Y; Sinielnikov I; Yang TS; Liang X; Chen C; Wang L; Cheng AL; Kaseb A; Vogel A;
Lancet; 2023 Sep; 402(10408):1133-1146. PubMed ID: 37499670
[TBL] [Abstract][Full Text] [Related]
26. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yang Y; Pan J; Wang H; Zhao Y; Qu S; Chen N; Chen X; Sun Y; He X; Hu C; Lin L; Yu Q; Wang S; Wang G; Lei F; Wen J; Yang K; Lin Z; Guo Y; Chen S; Huang X; Wu Y; Liang L; Chen C; Bai F; Ma X; Zhang Y; Leaw S; Zhang L; Fang W
Cancer Cell; 2023 Jun; 41(6):1061-1072.e4. PubMed ID: 37207654
[TBL] [Abstract][Full Text] [Related]
27. The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma.
Park SY; Kim HK; Jeon YJ; Lee J; Cho JH; Choi YS; Shim YM; Zo JI
Cancer Res Treat; 2023 Oct; 55(4):1231-1239. PubMed ID: 37114475
[TBL] [Abstract][Full Text] [Related]
28. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J; Kato K; Raymond E; Hubner RA; Shu Y; Pan Y; Park SR; Ping L; Jiang Y; Zhang J; Wu X; Yao Y; Shen L; Kojima T; Gotovkin E; Ishihara R; Wyrwicz L; Van Cutsem E; Jimenez-Fonseca P; Lin CY; Wang L; Shi J; Li L; Yoon HH
Lancet Oncol; 2023 May; 24(5):483-495. PubMed ID: 37080222
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.
Chen X; Xu X; Wang D; Liu J; Sun J; Lu M; Wang R; Hui B; Li X; Zhou C; Wang M; Qiu T; Cui S; Sun N; Li Y; Wang F; Liu C; Shao Y; Luo J; Gu Y
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759013
[TBL] [Abstract][Full Text] [Related]
30. The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies.
Testa U; Castelli G; Pelosi E
Curr Oncol; 2023 Jan; 30(1):610-640. PubMed ID: 36661697
[TBL] [Abstract][Full Text] [Related]
31. Expression of Inhibitory Receptors TIGIT, TIM-3, and LAG-3 on CD4+ T Cells from Patients with Different Clinical Forms of Chronic Chagas Disease.
Ferragut F; Alcaraz PB; Beati P; Girard MC; Ossowski MS; Chadi R; Fernández M; Hernández-Vásquez Y; Acevedo GR; Gómez KA
J Immunol; 2023 Mar; 210(5):568-579. PubMed ID: 36602929
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.
Li S; Yu W; Xie F; Luo H; Liu Z; Lv W; Shi D; Yu D; Gao P; Chen C; Wei M; Zhou W; Wang J; Zhao Z; Dai X; Xu Q; Zhang X; Huang M; Huang K; Wang J; Li J; Sheng L; Liu L
Nat Commun; 2023 Jan; 14(1):8. PubMed ID: 36596787
[TBL] [Abstract][Full Text] [Related]
33. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.
Liu Z; Zhao Y; Kong P; Liu Y; Huang J; Xu E; Wei W; Li G; Cheng X; Xue L; Li Y; Chen H; Wei S; Sun R; Cui H; Meng Y; Liu M; Li Y; Feng R; Yu X; Zhu R; Wu Y; Li L; Yang B; Ma Y; Wang J; Zhu W; Deng D; Xi Y; Wang F; Li H; Guo S; Zhuang X; Wang X; Jiao Y; Cui Y; Zhan Q
Cancer Cell; 2023 Jan; 41(1):181-195.e9. PubMed ID: 36584672
[TBL] [Abstract][Full Text] [Related]
34. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
35. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Wang Z; Wu L; Li B; Cheng Y; Li X; Wang X; Han L; Wu X; Fan Y; Yu Y; Lv D; Shi J; Huang J; Zhou S; Han B; Sun G; Guo Q; Ji Y; Zhu X; Hu S; Zhang W; Wang Q; Jia Y; Wang Z; Song Y; Wu J; Shi M; Li X; Han Z; Liu Y; Yu Z; Liu AW; Wang X; Zhou C; Zhong D; Miao L; Zhang Z; Zhao H; Yang J; Wang D; Wang Y; Li Q; Zhang X; Ji M; Yang Z; Cui J; Gao B; Wang B; Liu H; Nie L; He M; Jin S; Gu W; Shu Y; Zhou T; Feng J; Yang X; Huang C; Zhu B; Yao Y; Tang X; Yu J; Maher E; Feng H; Yao S; Keegan P; Wang J
J Clin Oncol; 2023 Jan; 41(3):651-663. PubMed ID: 36206498
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
37. Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Lu S; Fang J; Wang Z; Fan Y; Liu Y; He J; Zhou J; Hu J; Xia J; Liu W; Shi J; Yi J; Cao L
Cancer Med; 2023 Feb; 12(3):2666-2676. PubMed ID: 36052772
[TBL] [Abstract][Full Text] [Related]
38. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Jayaprakash V; Wei L; Ferris RL
Oncologist; 2022 Mar; 27(2):e194-e198. PubMed ID: 35641218
[TBL] [Abstract][Full Text] [Related]
39. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
[TBL] [Abstract][Full Text] [Related]
40. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
